TrialReader


Rota China Registry

NCT03806621 — Completed, 980 participants, Beijing Anzhen Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Post-Approval Study of the RotablatorTM Rotational Atherectomy System in China

RegistryNCT03806621
StatusCompleted
Study typeObservational
Enrollment980 (Actual)
SponsorBeijing Anzhen Hospital (Other); collaborators: BSC International Medical Trading (Shanghai) Co., Ltd.
ConditionsCoronary Artery Disease
InterventionsRotational Atherectomy (Procedure)
Datesstart 2018-07-18, primary completion 2020-12-27, completion 2022-01-20, first posted 2019-01-16, last updated 2023-08-08
Locations19 sites in China

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Coronary Artery Disease All trials of Rotational Atherectomy

-Summary

Rotational atherectomy (RA) facilitates percutaneous coronary intervention for complex de novo lesions with severe calcification. Some observational studies and a small randomized trial indicated that a strategy of routine RA did not conferred reduction in restenosis or MACE, but these studies are limited by missing follow-up, insufficient power to compare outcomes, and confounding factors in the RA group (long lesion length, etc.). With recent developments in medical therapy, advances in design and delivery of drug-eluting stents (DES), and advances in noninvasive and intravascular coronary imaging, the use of RA in current real-world practice remains to be well determined. We aimed to compile real-world clinical outcomes data for the RotablatorTM Rotational Atherectomy System in routine clinical practice in China.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Rotational AtherectomyProcedure: Rotational Atherectomy
  • Rotational Atherectomy (Procedure): Patients with severe calcified lesions will receive rotational atherectomy during index PCI

+Outcome measures

Primary outcomes

  • Major adverse cardiovascular event (MACE) (primary safety endpoint) [30 days]: The composite of any ischemia-driven target lesion revascularization (TLR), myocardial infarction (MI), or cardiac death. Periprocedural myocardial infarction, defined as in patients with normal baseline CK-MB, the peak CK-MB measured within 48 hours of the procedure rises to ≥ 10 x the local laboratory ULN, or to ≥ 5 x ULN with new pathologic Q-waves in ≥ 2 contiguous leads or new persistent LBBB (according to SCAI definition. J Am Coll Cardiol 2013;62:1563-70)
  • Procedural success rate (primary efficacy endpoint) [Peri-procedural]: A mean lesion diameter stenosis <30% in 2 near-orthogonal projections with TIMI 3 flow, as visually assessed by the physician, without the occurrence of in-hospital MI, target vessel revascularization (TVR), or cardiac death

Secondary outcomes

  • TLR rate [At 30 days and 12 months post-index procedure]
  • Target lesion failure (TLF) rate [At 30 days and 12 months post-index procedure]
  • TVR rate [At 30 days and 12 months post-index procedure]
  • Target vessel failure (TVF) rate [At 30 days and 12 months post-index procedure]
  • MI rate [At 30 days and 12 months post-index procedure]
  • Cardiac death rate [At 30 days and 12 months post-index procedure]
  • Non-cardiac death rate [At 30 days and 12 months post-index procedure]
  • All-cause death rate [At 30 days and 12 months post-index procedure]
  • Cardiac death or MI rate [At 30 days and 12 months post-index procedure]
  • All-cause death or MI rate [At 30 days and 12 months post-index procedure]
  • All-cause death, MI, or TVR rate [At 30 days and 12 months post-index procedure]
  • Stent thrombosis (ST) rate [At 30 days and 12 months post-index procedure]
  • Subgroup analyses of MACE [At 30 days and 12 months post-index procedure]: 1\. Age (< 65 years vs. ≥ 65 years), 2. Female, 3. Hypertension, 4. Diabetes, 5. CKD, 6. Left ventricular ejection fraction (≤ 50% vs. > 50%), 7. LM lesion, 8. Long lesion, 9. CTO, 10. Bifurcation lesion, 11. Speed of rotation, 12. Maximal burr size, 13. IVUS or OCT use

Other outcomes

  • Rate of arterial perforation (rotational atherectomy related or non-related) [Peri-procedural]
  • Rate of abrupt coronary occlusion (including dissection and thrombosis) [Peri-procedural]
  • Rate of significant coronary dissection (NHLBI types C-F) [Peri-procedural]
  • Rate of consistent no reflow [Peri-procedural]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Age ≥18 years old
* Subject who is clinically indicated for PCI/stenting
* Written informed consent
* Subject is willing to comply with all protocol-required follow-up evaluation
* Subject must meet one of following angiographic/procedural inclusion criteria:

  * Target lesion is moderately to severely calcified by visual estimate
  * Unsuccessful balloon dilatation of the target lesion
  * Unsuccessful passage of device(s) (microcatheter, balloon, or stent) across the target lesion

Exclusion Criteria:

* Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute MI within 2 weeks
* Subject has any of the following angiographic findings:

  * Thrombus present in the target vessel (by visual estimate)
  * Significant dissection present in the target vessel (NHLBI types C-F)
  * Lesion angulation > 60°(by visual estimate)

+Locations (19)

FacilityCityCountryStatus
The First Affiliated Hospital of USTCHefei, AnhuiChina
Beijing Anzhen Hospital, Capital Medical UniversityBeijing, Beijing MunicipalityChina
Beijing HospitalBeijing, Beijing MunicipalityChina
Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, Beijing MunicipalityChina
Peking Union Medical College HospitalBeijing, Beijing MunicipalityChina
Guangdong Provincial People's Hospital, Guangdong Academy of Medical ScienceGuangzhou, GuangdongChina
The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, GuangdongChina
Fuwai Central China Cardiovascular HospitalZhengzhou, HenanChina
The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, HenanChina
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, HubeiChina
Nanjing First hospital, Nanjing Medical UniversityNanjing, JiangsuChina
First Hospital of China Medical UniversityShenyang, LiaoningChina
The First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ShaanxiChina
Xijing Hospital, the Fourth Military Medical UniversityXi'an, ShaanxiChina
Qilu Hospital (Qingdao), Shandong UniversityJinan, ShandongChina
West China Hospital, Sichuan UniversityChengdu, SichuanChina
Tianjin Fourth Central HospitalTianjin, Tianjin MunicipalityChina
The First People's Hospital of Yunnan ProvinceKunming, YunnanChina
Sir Run Run Shaw Hospital, Zhejiang University School of MedicineHangzhou, ZhejiangChina

+Publications

  • Results publication: Wang X, Zhang H, Bai X, Zhang L, Li C, Mao X, Chen J, Luo J, Zhao Y, Zhou B, You B, Zhang Y, Ma L, Du Z, Chen Y, Sun F, Qiu C, Shen Z, Wen S, Mintz GS, Ye F, Nie S; China Rota Elite Group. Practices and outcomes of rotational atherectomy in China: The Rota China registry. Catheter Cardiovasc Interv. 2024 Oct;104(4):664-675. doi: 10.1002/ccd.31211. Epub 2024 Sep 3. PMID 39223992

My Notes